Erowid References Database
|
Longo VG, Loizzo A.
“Evaluation of the Central Effects of Ergot Alkaloids by Means of Electroencephalography”.
Pharmacology. 1978;16(Suppl. 1):189-92.
|
|
Abstract
The evaluation of the central effects of ergot alkaloids (HA) with EEG is discussed. Early studies found that ergotamine (1 mg/kg, i.v.; 0.02 mg i.c.; cat), DH-ergotamine (1 mg/kg i.v., cat and 1-2 mg/kg i.v. rabbit), Hydergine (0.1 mg i.c., rabbit) and bromocriptine (CB 154, B. 0.06 mg i.c., rat) had little effect on the EEG. Studies using the rabbit and d-lysergic acid diethylamide, d lysergic acid pyrrolidide, d-lysergic acid monoethylamide, d lysergic acid propanolamide, d-lysergic acid butanolamide, 2 brom lysergic acid diethylamide, 1-methyl lysergic acid butanolamide, d-isolysergic acid diethylamide, showed that EEG alterations were found at the level of the hippocampus with drugs demonstrating psychodysleptic activity in man. Interaction with the central serotonergic system is postulated as the mechanism of action of these drugs. B ( < 10 mg/kg, i.v.) did not activate rabbit EEG, unlike amphetamine (1-2 mg/kg) or L-dopa (20-40 mg/kg), nor did B (0.06 ma) alter EEG in rats when administered intraventricularly. Stereotypy was seen in cats following ergotamine (20 mcg intraventricularly) and rats after agroclavine (1-2 mg/kg). Ergotoxin altered central neuroendocrine regulatory systems. Some ol’gopeptides potentiated the behavioural actions of L dopa and 5-hydroxytryptophan (5-HTP) however B (10 mg/kg i.p.) did not alter symptoms produced with L-dopa (100 mg/kg i.p.) or 5-HTP (75 mg/kg i.p.) in pargyline pretreated mice. Conclusion EAs may possess a dopaminergic moiety which is responsible for the neuroendocrine actions.
|
| # |
| Submit Comment |
|
[
Cite HTML ]
